Effect of angiotensin converting enzyme gene polymorphism on patients with in-stent restenosis after percutaneous coronary intervention

被引:3
作者
Abdelaziz, Tarek A. [1 ]
Mohamed, Randa H. [2 ]
Balata, Gehan F. [3 ]
El-Azzazy, Omar Y. [4 ]
机构
[1] Zagazig Univ, Fac Med, Dept Cardiol, Zagazig, Egypt
[2] Zagazig Univ, Fac Med, Dept Med Biochem, Zagazig, Egypt
[3] Zagazig Univ, Fac Pharm, Dept Pharmaceut, Zagazig, Egypt
[4] Zagazig Univ, Fac Pharm, Dept Pharm Practice, Zagazig, Egypt
关键词
ACE gene; In-stent restenosis; Polymorphism; Coronary artery disease; ARTERY-DISEASE; INHIBITORS;
D O I
10.4314/tjpr.v20i2.26
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To evaluate the association between common single nucleotide polymorphisms (SNPs) in angiotensin converting enzyme (ACE) gene and the risk of in-stent restenosis (ISR) and/or the response to angiotensin converting enzyme inhibitor ACEI in individuals with stable coronary artery disease (CAD) after stent implantation. Methods: The total population of this study consisted of 200 Egyptian individuals divided into 2 groups - in-stent restenosis (ISR) and non ISR group). Genomic DNA was withdrawn from EDTA whole blood applying a spin column approach and ACE gene insertion/deletion (I/D) polymorphisms were determined by polymerase chain reaction (PCR). Results: Carriers of allele D of ACE gene were significantly more liable to ISR occurrence. However, carriers of allele I were significantly more liable to ISR occurrence after administration of ACEI. There is a negative interaction between DD genotype of ACE gene and ACEI administration on ISR after percutaneous coronary intervention (PCI). However, there is a positive interaction between II and ID genotype of ACE gene and ACEI administration on ISR after PCI with bare metal stents (BMS). Conclusion: It is beneficial to implement ACEI in therapeutic regimen in individuals with ID or II genotypes of ACE gene, especially with BMS implementation.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 23 条
  • [1] A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: Evidence for publication bias
    Agema, WRP
    Jukema, JW
    Zwinderman, AH
    van der Wall, EE
    [J]. AMERICAN HEART JOURNAL, 2002, 144 (05) : 760 - 768
  • [2] Attallah N, 2005, CLIN NEPHROL, V64, P412
  • [3] Baris N, 2004, ARCH TURKISH SOC CAR, V32, P107
  • [4] Blendea C., 2016, ACTA MED MARISIENSIS, V62, P64, DOI DOI 10.1515/AMMA-2015-0123
  • [5] Pharmacogenetics:: data, concepts and tools to improve drug discovery and drug treatment
    Brockmoeller, Juergen
    Tzvetkov, Mladen V.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (02) : 133 - 157
  • [6] ANGIOTENSIN-CONVERTING ENZYME IN THE HUMAN HEART - EFFECT OF THE DELETION INSERTION POLYMORPHISM
    DANSER, AHJ
    SCHALEKAMP, MADH
    BAX, WA
    VANDENBRINK, AM
    SAXENA, PR
    RIEGGER, GAJ
    SCHUNKERT, H
    [J]. CIRCULATION, 1995, 92 (06) : 1387 - 1388
  • [7] Ekizler F., 2018, AM J CARDIOL, V121, pe70
  • [8] The endothelial nitric oxide synthase (Glu298Asp and-786T>C) gene polymorphisms are associated with coronary in-stent restenosis
    Gomma, AH
    Elrayess, MA
    Knight, CJ
    Hawe, E
    Fox, KM
    Humphries, SE
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 (24) : 1955 - 1962
  • [9] The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis - Role of angiotensin converting enzyme inhibitors in stent restenosis in patients with diabetes mellitus
    Guneri, S
    Baris, N
    Aytekin, D
    Akdeniz, B
    Pekel, N
    Bozdemir, V
    [J]. INTERNATIONAL HEART JOURNAL, 2005, 46 (05) : 889 - 897
  • [10] In-Stent Restenosis
    Kim, Michael S.
    Dean, Larry S.
    [J]. CARDIOVASCULAR THERAPEUTICS, 2011, 29 (03) : 190 - 198